4 (1 votes)
Around 75% of the 48,000 women annually diagnosed with breast cancer in the UK suffer from an estrogen receptor positive tumor, which implies the involvement of the hormone estrogen in cancer growth. Tamoxifen and exemestane are both hormone treatments, and whilst tamoxifen blocks the tumor's ability to use estrogen, aromatase inhibitors, such as exemestane reduce the body's production of estrogen.
Findings in The Lancet Oncology now reveal that a drug therapy that reduces the risk of women dying from breast cancer exposes these women to a higher risk of developing carpal tunnel syndrome, however, this can be managed and does not persist once treatment has finished.
Women with early stage estrogen receptor-positive (ER
No comments:
Post a Comment